36 Result(s)
within
Diego F. Calvisi
English
-
Article
Open AccessOverexpression of TBX3 suppresses tumorigenesis in experimental and human cholangiocarcinoma
TBX3 behaves as a tumor suppressor or oncoprotein across cancer. However, TBX3 function remains undetermined in intrahepatic cholangiocarcinoma (iCCA), a deadly primary liver malignancy with few systemic treat...
-
Article
Open AccessIdentification of DUSP4/6 overexpression as a potential rheostat to NRAS-induced hepatocarcinogenesis
Upregulation of the mitogen-activated protein kinase (MAPK) cascade is common in hepatocellular carcinoma (HCC). Neuroblastoma RAS viral oncogene homolog (NRAS) is mutated in a small percentage of HCC and is hith...
-
Article
Open AccessLoss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis
Hepatocellular carcinoma (HCC) is a deadly malignancy with high genetic heterogeneity. TP53 mutation and c-MET activation are frequent events in human HCCs. Here, we discovered that the simultaneous mutations in
-
Article
Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance
Cholangiocarcinoma (CCA) is a rare malignancy that develops at any point along the biliary tree. CCA has a poor prognosis, its clinical management remains challenging, and effective treatments are lacking. The...
-
Article
Open AccessA new mission for an old anti-cancer drug: harnessing hepatocyte-specific metabolic pathways against liver tumors
-
Article
Open AccessCorrection: The Hippo pathway efector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease
-
Article
Open AccessCorrection: CD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype
-
Article
Open AccessCritical evaluation of molecular tumour board outcomes following 2 years of clinical practice in a Comprehensive Cancer Centre
Recently, molecular tumour boards (MTBs) have been integrated into the clinical routine. Since their benefit remains debated, we assessed MTB outcomes in the Comprehensive Cancer Center Ostbayern (CCCO) from 2...
-
Article
Open AccessCrenigacestat blocking notch pathway reduces liver fibrosis in the surrounding ecosystem of intrahepatic CCA viaTGF-β inhibition
Intrahepatic cholangiocarcinoma (iCCA) is a highly malignant tumor characterized by an intensive desmoplastic reaction due to the exaggerated presence of the extracellular (ECM) matrix components. Liver fibrob...
-
Article
Open AccessThe Hippo pathway effector TAZ induces intrahepatic cholangiocarcinoma in mice and is ubiquitously activated in the human disease
Intrahepatic cholangiocarcinoma (iCCA) is a highly aggressive primary liver tumor with increasing incidence worldwide, dismal prognosis, and few therapeutic options. Mounting evidence underlines the role of th...
-
Article
Open AccessCD90 is regulated by notch1 and hallmarks a more aggressive intrahepatic cholangiocarcinoma phenotype
Intrahepatic Cholangiocarcinoma (iCCA) is characterized by a strong stromal reaction playing a role in tumor progression. Thymus cell antigen 1 (THY1), also called Cluster of Differentiation 90 (CD90), is a key r...
-
Article
Open AccessAlpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the sixth most common primary cancer with an unsatisfactory long-term survival. Gain of function mutations of PIK3CA occur in a subset of human HCC. Alpelisib, a selective PIK3CA...
-
Article
Open AccessAutopsy findings after long-term treatment of COVID-19 patients with microbiological correlation
Between April and June 2020, i.e., during the first wave of pandemic coronavirus disease 2019 (COVID-19), 55 patients underwent long-term treatment in the intensive care unit at the University Hospital of Rege...
-
Article
Open AccessFascin1 empowers YAP mechanotransduction and promotes cholangiocarcinoma development
Mechanical forces control cell behavior, including cancer progression. Cells sense forces through actomyosin to activate YAP. However, the regulators of F-actin dynamics playing relevant roles during mechanost...
-
Article
Open AccessDistinct functions of transforming growth factor-β signaling in c-MYC driven hepatocellular carcinoma initiation and progression
Dysregulation of transforming growth factor-beta (TGFβ) signaling has been implicated in liver carcinogenesis with both tumor promoting and inhibiting activities. Activation of the c-MYC protooncogene is anoth...
-
Article
Open AccessNuclear ErbB2 expression in hepatocytes in liver disease
ErbB2 is a prominent representative of the epidermal growth factor receptors that mainly attract attention as oncogenic drivers and therapeutic targets in cancer. Besides transmembrane signaling, ErbB2 may als...
-
Article
Open AccessCholangiocarcinoma 2020: the next horizon in mechanisms and management
Cholangiocarcinoma (CCA) includes a cluster of highly heterogeneous biliary malignant tumours that can arise at any point of the biliary tree. Their incidence is increasing globally, currently accounting for ~...
-
Article
Open AccessCrenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis
Intrahepatic cholangiocarcinoma (iCCA) is a deadly disease with rising incidence and few treatment options. An altered expression and/or activation of NOTCH1–3 receptors has been shown to play a role in iCCA d...
-
Article
Harnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the most common form of primary adult liver cancer. After nearly a decade with sorafenib as the only approved treatment, multiple new agents have demonstrated efficacy in clin...
-
Article
Publisher Correction: Harnessing big ‘omics’ data and AI for drug discovery in hepatocellular carcinoma
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
